Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 1,073,474 shares, a growth of 8,549.4% from the May 31st total of 12,411 shares. Based on an average daily volume of 24,954 shares, the days-to-cover ratio is currently 43.0 days.
Innovent Biologics Stock Down 7.6%
Shares of OTCMKTS IVBXF traded down $0.78 during mid-day trading on Thursday, hitting $9.51. The stock had a trading volume of 2,858 shares, compared to its average volume of 4,899. The business has a 50 day moving average price of $10.35 and a two-hundred day moving average price of $10.61. Innovent Biologics has a 1 year low of $9.10 and a 1 year high of $15.12.
Innovent Biologics Company Profile
Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.
The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).
Recommended Stories
- Five stocks we like better than Innovent Biologics
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
